---
title: "The Nasdaq Biotechnology Index rose by 1.56%. Among the constituent stocks, Sutro Biopharma increase"
description: "The Nasdaq Biotechnology Index rose by 1.56%. Among the constituent stocks, Sutro Biopharma increased by 20.04%, Mersana Therapeutics rose by 17.19%, and Neurogene climbed by 15.12%. Tempus AI fell by"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/238371651.md"
published_at: "2025-04-30T21:34:23.000Z"
---

# The Nasdaq Biotechnology Index rose by 1.56%. Among the constituent stocks, Sutro Biopharma increase

> The Nasdaq Biotechnology Index rose by 1.56%. Among the constituent stocks, Sutro Biopharma increased by 20.04%, Mersana Therapeutics rose by 17.19%, and Neurogene climbed by 15.12%. Tempus AI fell by 4.83%, Prothena Plc. decreased by 5.06%, Grail dropped by 6.28%, and OmniAb declined by 8.11%

The Nasdaq Biotechnology Index closed up 1.56%. Component stocks Sutro Biopharma rose 20.04%, Mersana Therapeutics rose 17.19%, and Neurogene rose 15.12%. Tempus AI fell 4.83%, ranking fourth from the bottom, Prothena Plc. fell 5.06%, Grail fell 6.28%, and OmniAb fell 8.11%

### Related Stocks

- [STRO.US - Sutro Biopharma](https://longbridge.com/en/quote/STRO.US.md)
- [NGNE.US - Neurogene](https://longbridge.com/en/quote/NGNE.US.md)
- [TEM.US - Tempus AI](https://longbridge.com/en/quote/TEM.US.md)
- [OABI.US - OmniAb](https://longbridge.com/en/quote/OABI.US.md)
- [PRTA.US - Prothena](https://longbridge.com/en/quote/PRTA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Neurogene 公司规划了 NGN-401 的关键 Rett 综合症研究时间线，并将在 2026 年中期于古根海姆峰会上更新数据 | Neurogene（纳斯达克股票代码：NGNE）正在推进其基因药物管线，重点关注雷特综合症，其主要项目为 NGN-401。在古根海姆峰会上，总裁兼首席财务官 Christine Mikail 概述了关键研究的时间表，预计将在 2025 年第 | [Link](https://longbridge.com/en/news/275981671.md) |
| Neurogene 根据激励计划向新员工授予股票期权 | Neurogene Inc. 根据其 2025 年诱导计划向一名新员工授予了非合格股票期权，允许购买 2,820 股普通股。期权的行使价格等于 2026 年 2 月 2 日授予日期的收盘价，并将在四年内逐步归属，第一年归属 25%，其余部分 | [Link](https://longbridge.com/en/news/274864877.md) |
| Sutro Biopharma 宣布进行 1.1 亿美元的股票发行 | Sutro Biopharma Inc. 宣布签署了一项约 1.1 亿美元的股票配售，发行 7,868,383 股，每股价格为 13.98 美元。此次融资的收益将主要用于产品候选者的研究、临床开发、工艺开发和制造，以及一般企业用途。此次融资 | [Link](https://longbridge.com/en/news/275454418.md) |
| Neurogene 通过 Embolden 试验的剂量推进 NGN-401 基因疗法用于 Rett 综合症，并即将迎来 2026 年的里程碑 | Neurogene Inc. 在其针对 Rett 综合症的 NGN-401 基因疗法方面取得了显著进展，多个参与者已在 Embolden 试验中接受了治疗。预计给药将在 2026 年第二季度结束，期间的安全性和有效性数据将于 2026 年中 | [Link](https://longbridge.com/en/news/272264619.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.